NSAIDs: A Faustian bargain

American Journal of Nursing

Volumn 100, Issue 6, 2000, Pages 34-39

  Peloso, Paul M ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIULCER AGENT; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT;

CHEMICALLY INDUCED DISORDER; DRUG COST; DRUG EFFECT; ECONOMICS; GASTROINTESTINAL DISEASE; HUMAN; NURSING; REVIEW; RISK FACTOR; STOMACH MUCOSA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; DRUG COSTS; GASTRIC MUCOSA; GASTROINTESTINAL DISEASES; HUMANS; MISOPROSTOL; RISK FACTORS;

EID: 0041408419     PISSN: 0002936X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000446-200006000-00050     Document Type: Article

References (43)

1. Gibson T. Nonsteroidal anti-inflammatory drugs - another look. Br J Rheumatol 1988;27(2):87-90.
2. Baum C, et al. Utilization of nonsteroidal antiinflarnmatory drugs. Arthritis Rheum 1985;28(6):686-92.
3. Zeidler H. Epidemiology and economics of NSAID-induced gastropathy. Scand J Rheumatol Suppl 1992;92:3-8.
4. Physicians' desk reference. 54th ed. Montvale (NJ): Medical Economics; 2000.
5. Cooke CE. Disease management: prevention of NSAID-induced gastropathy. Drug Benefit Trends 1996;8:14-5, 9-22.
6. Gabriel SE, et al. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115(10):787-96.
7. Fries JF, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991;91(3):213-22.
8. Geis GS, et al. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol Suppl 1991;28:11-4.
9. Graham DY. High-dose famotidine for prevention of NSAID ulcers? [editorial; comment]. Gastroenterology 1997;112(6):2143-5.
10. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988;84(2A):20-4.
11. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231(25):232-5.
12. Soll AH, et al. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991;114(4):307-19.
13. Kaufmann W, et al. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996;93(2317-21):6.
14. Harris RC, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94(6):2504-10.
15. Vane JR, Boning RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol Suppl 1996;102:9-21.
16. Stern AI, et al. Lack of gastric mucosal protection by sucralfate during long-term aspirin ingestion in humans. Am J Med 1989;86(6A):66-9.
17. Robinson MG, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989;34(3):424-8.
18. Ehsanullah RS, et al. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988;297(6655):1017-21.
19. Koch M, et al. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 1996;156(20):2321-32.
20. Scheiman JM, et al. Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci 1994;39(1):97-103.
21. Oddsson E, et al. Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen. Scand J Gastroenterol 1992;27(12):1045-8.
22. Ekstrom P, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996;31(8):753-8.
23. Avorn J, et al. Epidemiologic analysis of prophylactic drug use and NSAID gastropathy. Arthritis Rheum 1996;39:S165.
24. Hawkey CJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338(11):727-34.
25. Steiner JA. Misoprostol clinical pharmacology. Establishment of activity in man. Dig Dis Sci 1985;30(11 Suppl):136S-41S.
26. Peloso P, et al. Balancing patient well-being and drug toxicity: lessons from the use of misoprostol in rheumatology. Arthritis Rheum 1996;39(9 Suppl):S165.
27. Lanza FL. A double-blind study of prophylactic effect of misoprostol on lesions of gastric and duodenal mucosa induced by oral administration of tolmetin in healthy subjects. Dig Dis Sci 1986;31(2 Suppl):131S-6S.
28. Aadland E, et al. Protection by misoprostol against naproxen-induced gastric mucosal damage. Am J Med 1987;83(1A):37-40.
29. Graham DY, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 1993;119(4):257-62.
30. Silverstein FE, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123(4):241-9.
31. Simon LS, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282(20):1921-8.
32. Lanza FL, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999;13(6):761-7.
33. Verdickt W, et al. A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis. Scand J Rheumatol 1992;21(2):85-91.
34. Agrawal NM, et al. Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Clin Ther 1999;21(4):659-74.
35. Bocanegra TS, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group. J Rheumatol 1998;25(8):1602-11.
36. Melo Gomes JA, et al. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993;52(12):881-5.
37. Singh G, et al. Gastrointestinal tract complications of non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996;156(14):1530-6.
38. De Pouvourville G. The economic consequences of NSAID-induced gastropathy: the French context. Scand J Rheumatol 1992;96(Suppl):49-53.
39. Gabriel SE, et al. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993;36(4):447-59.
40. Carrin GJ, Torfs KE. Economic evaluation of prophylactic treatment with Misoprostol in osteoarthritic patients treated with NSAIDs. The case of Belgium. Rev Epidemiol Sante Publique 1990;38(3):187-99.
41. Knill-Jones R, et al. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal antiinflammatory drugs. Postgrad Med J 1990;66(778):639-46.
42. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking non-steroidal anti-inflammatory drugs. Arch Intern Med 1989;149(9):2061-5.
43. Maetzel A, et al. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1998;41(1):16-25.